U.S. lawmakers demand details from Novartis and AT&T about their payments to Cohen's firm.
The most innocent explanation of the payments to Michael Cohen's LLC is still pretty sketchy.
The catch: It costs $475,000.
A new cancer drug won enthusiastic support from a federal advisory panel.
I want to share a personal moment for National Family Caregivers Month. It's one that will always stand out with me and my family, and it may resonate with others going through similar situations. It's the day my mom was diagnosed with heart failure, and the moment I became her caregiver and advocate-in-chief.
Recent memos allegedly leaked from the Colombian Embassy in Washington describe intense pressure by the pharmaceutical industry to discourage Colombia's efforts to half the local price of Novartis' Gleevec, one of the leading medications used to treat Chronic Myelogenous Leukemia (CML).
A leaked Colombian Embassy memo suggests the U.S. wants to preserve the high price of cancer drug Gleevec.
Tamara Jacobs knows what she's talking about when it comes to moving ahead in the business world. When Fortune 500 companies like Pfizer, Johnson & Johnson, Bayer, Merck, Novartis, Revlon, and others need advice with their branding and image, they call Tamara.
In one alleged case, Novartis offered a Los Angeles pharmacist a "bonus" rebate of 5 percent of that pharmacist's annual
The costs of protectionism can be large, as economists frequently point out when discussing 20 percent tariffs in steel. For some reason they become strangely silent when it comes to patent protection that raise the price of drugs by 1,000 percent.
India is actually at the forefront of providing affordable medicine to its citizens, which is a vast improvement over the healthcare system in the US.
India's Supreme Court on Monday rejected drug maker Novartis AG's attempt to patent a new version of a cancer drug in a landmark decision that healthcare activists say ensures poor patients around the world will get continued access to cheap versions of lifesaving medicines.